De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
TG Therapeutics Balans Gezondheid
Financiële gezondheid criteriumcontroles 6/6
TG Therapeutics heeft een totaal eigen vermogen van $177.6M en een totale schuld van $102.9M, wat de schuld-eigenvermogensverhouding op 58% brengt. De totale activa en totale passiva bedragen respectievelijk $401.2M en $223.6M. De EBIT TG Therapeutics is $101.8M waardoor de rentedekking 8.2 is. Het heeft contanten en kortetermijnbeleggingen van $217.3M.
Belangrijke informatie
58.0%
Verhouding schuld/eigen vermogen
US$102.92m
Schuld
| Rente dekkingsratio | 8.2x |
| Contant | US$217.25m |
| Aandelen | US$177.57m |
| Totaal verplichtingen | US$223.64m |
| Totaal activa | US$401.21m |
Recente financiële gezondheidsupdates
TG Therapeutics (NASDAQ:TGTX) Has A Pretty Healthy Balance Sheet
Aug 02
TG Therapeutics (NASDAQ:TGTX) Has A Somewhat Strained Balance Sheet
Mar 25Does TG Therapeutics (NASDAQ:TGTX) Have A Healthy Balance Sheet?
Nov 24Is TG Therapeutics (NASDAQ:TGTX) A Risky Investment?
Jul 19Is TG Therapeutics (NASDAQ:TGTX) Using Debt In A Risky Way?
Apr 13Is TG Therapeutics (NASDAQ:TGTX) Weighed On By Its Debt Load?
Jan 02Recent updates
TG Therapeutics, Inc.'s (NASDAQ:TGTX) Shares Bounce 27% But Its Business Still Trails The Industry
Sep 01Results: TG Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Aug 09TG Therapeutics Delivers A Beat-And-Raise Q2 And A $100 Million Buyback
Aug 07TG Therapeutics (NASDAQ:TGTX) Has A Pretty Healthy Balance Sheet
Aug 02Hold TG Therapeutics For Intriguing Outcomes
Jun 12TG Therapeutics, Inc. (NASDAQ:TGTX) Surges 25% Yet Its Low P/S Is No Reason For Excitement
May 29TG Therapeutics, Inc. (NASDAQ:TGTX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
May 04TG Therapeutics: Less Room For Doubt About Briumvi
May 03News Flash: Analysts Just Made A Meaningful Upgrade To Their TG Therapeutics, Inc. (NASDAQ:TGTX) Forecasts
May 03TG Therapeutics (NASDAQ:TGTX) Has A Somewhat Strained Balance Sheet
Mar 25TG Therapeutics: Briumvi Growth Story Appears Intact
Mar 01Results: TG Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Mar 01TG Therapeutics Made A Strong Impression At The J.P. Morgan Healthcare Conference
Jan 10Some Confidence Is Lacking In TG Therapeutics, Inc.'s (NASDAQ:TGTX) P/S
Jan 04Does TG Therapeutics (NASDAQ:TGTX) Have A Healthy Balance Sheet?
Nov 24TG Therapeutics, Inc. (NASDAQ:TGTX) Not Flying Under The Radar
Sep 30Upgrade: Analysts Just Made A Stunning Increase To Their TG Therapeutics, Inc. (NASDAQ:TGTX) Forecasts
Aug 03Is TG Therapeutics (NASDAQ:TGTX) A Risky Investment?
Jul 19Is TG Therapeutics (NASDAQ:TGTX) Using Debt In A Risky Way?
Apr 13Is TG Therapeutics (NASDAQ:TGTX) Weighed On By Its Debt Load?
Jan 02TG Therapeutics: Elucidating The Upcoming Binary
Oct 09TG Therapeutics: We Are Just Hanging In There
Sep 21Despite Lacking Profits TG Therapeutics (NASDAQ:TGTX) Seems To Be On Top Of Its Debt
Sep 07TG Therapeutics announces peer-reviewed publication of multiple sclerosis phase 3 trials
Aug 25TG Therapeutics Q2 2022 Earnings Preview
Aug 05TG Therapeutics And Ublituximab: From Icing To Lifeline
Jul 08Is TG Therapeutics (NASDAQ:TGTX) A Risky Investment?
Jun 06Analyse van de financiële positie
Kortlopende schulden: De korte termijn activa ( $389.2M ) TGTX } overtreffen de korte termijn passiva ( $108.7M ).
Langlopende schulden: De kortetermijnactiva TGTX ( $389.2M ) overtreffen de langetermijnschulden ( $115.0M ).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: TGTX heeft meer geld in kas dan de totale schuld.
Schuld verminderen: De schuld/eigen vermogen-ratio van TGTX is de afgelopen 5 jaar gedaald van 217% naar 58%.
Schuldendekking: De schuld van TGTX wordt goed gedekt door de operationele kasstroom ( 65.9% ).
Rentedekking: De rentebetalingen op de schuld van TGTX worden goed gedekt door EBIT ( 8.2 x dekking).